WO2005085292A2 - Procede de detection de la forme libre activable du psa et son utilisation pour le diagnostic des pathologies benignes de la prostate et de l'adenocarcinome de la prostate - Google Patents
Procede de detection de la forme libre activable du psa et son utilisation pour le diagnostic des pathologies benignes de la prostate et de l'adenocarcinome de la prostate Download PDFInfo
- Publication number
- WO2005085292A2 WO2005085292A2 PCT/FR2005/050132 FR2005050132W WO2005085292A2 WO 2005085292 A2 WO2005085292 A2 WO 2005085292A2 FR 2005050132 W FR2005050132 W FR 2005050132W WO 2005085292 A2 WO2005085292 A2 WO 2005085292A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- psa
- prostate
- activatable
- adenocarcinoma
- hbre
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
- G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
- G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
Definitions
- the present invention relates to the diagnosis of adenocarcinomas of the prostate.
- the subject of the invention is a method of diagnosing a benign pathology of the prostate or of an adenocarcinoma of the prostate in a patient suspected of being affected by such pathologies by using binding partners capable of recognizing this.
- specific prostate antigen or PSA, for Prostate Specifies Antigen
- PSA is produced by the glandular epithelium of the human prostate, probably in an inactive zymogenic form (Lundwall et al. FEBS Lett.
- PSA is the main marker of prostate cancer, which will affect one in six men in the West during their lifetime.
- PSA protease of the kallikrein family, mainly secreted by the prostatic epithelium, is found at a concentration of 0, 5 to 5 mg / l in the seminal fluid and at a concentration a million times lower in the serum of a patient
- PSA is normally found at a concentration lower than 2.5 ng ml in the serum.
- this concentration increases in principle notably during prostate cancer and during benign alterations such as benign prostatic hyperplasia (BPH) or acute prostatitis.
- BPH benign prostatic hyperplasia
- the protein sequence of PSA has been determined. It is a glycoprotein comprising 237 amino acids ("Molecular cloning of human prostate specifies antigen cDNA". Lundwall A., Lilja H., 1987.
- patent application WO97 / 12245 describes a method making it possible to diagnose an adenocarcinoma of the prostate without biopsy. This method involves measuring the total amount of PSA in the patient's serum or blood. If this value is between 2.5 and 20 ng / ml, the concentration of free PSA is also measured. The free PSA to total PSA ratio is then calculated. If this ratio is less than 7%, the diagnosis is directed towards an adenocarcinoma of the prostate.
- the use of a 7% threshold for the diagnosis of prostate cancer is controversial by many authors, as shown in the publication by Lein et al.
- the molecular forms of serum PSA from cancer patients or of BPH were mapped by two-dimensional electrophoresis, associated with clumioluminescence detection, in order to observe all of the forms of PSA, that is to say the free forms, including cleaved forms, and complexed forms.
- the electrophoresis profiles of sera from subjects suffering from prostate adenocarcinoma are relatively homogeneous, presenting essentially the non-cleaved free forms of PSA, while those of subjects suffering from BPH may comprise a relatively large proportion of cleaved free forms and slightly more basic spots without cleaved form.
- the increase in the ratio of serum free PSA to total serum PSA observed in patients with BPH is therefore essentially linked to the existence of cleaved free PSA, which could be enzymatically inactive and therefore incapable of binding to ACT, as well as 'to the presence of a slightly more basic form of free PSA than the active free PSA form, which could correspond to the zymogenic, inactive form of PSA.
- the Applicant has described methods for diagnosing prostate adenocarcinoma comprising the quantification, after separation by two-dimensional electrophoresis, of the cleaved and / or uncleaved free PSA and the use of these values in order to establish a diagnostic.
- the subject of the present invention is a method of in vitro diagnosis of a benign pathology of the prostate or of an adenocarcinoma of the prostate, characterized in that it comprises the step of detection, in a biological sample derived from a patient suspected of having a benign prostate disease or an adenocarcinoma of the prostate, of the activatable free form of PSA.
- the different forms of PSA present in biological fluids such as the seminal fluid or the serum of a patient have often had different names according to the authors. All agree that total PSA comes in two forms: the free form (free PSA) and the form complexed with this protease inhibitors such as TACT (complexed PSA).
- Free PSA can also be named according to its size: when it is produced in the form of ProPSA, it has additional amino acids (7 or 5 or 4 or 2). This is called zymogenic PSA or ProPSA-7, ProPSA-5, etc.
- This proPSA after maturation and therefore loss of its additional amino acids, can be found either in intact form or in partial form. In the latter case, we speak of truncated or cleaved PSA.
- Free PSA in intact form can also be denatured (glycosylated or deglycosylated); we then speak of a distorted form.
- the free PSA forms include zymogenic PSA, intact PSA, denatured or not, and cleaved PSA.
- active form is meant the forms being capable of binding to protease inhibitors, such as TACT.
- inactive form is meant the forms incapable of such a binding capacity.
- this activatable free form of PSA would, after activation, be equivalent to the form of PSA which complexes with ACT.
- This free activatable form would be a form of "closed” PSA, trapping the site of attachment to ACT, its activation making it possible to transform the "closed” form into an "open” form and thus release the site of fixation.
- the diagnostic method of the invention can be implemented either using a binding partner capable of binding specifically to activatable free PSA, or a binding partner capable of binding to non-specifically activatable free PSA.
- the invention relates to a method of in vitro diagnosis of a benign prostate pathology or of an adenocarcinoma of the prostate, characterized in that it comprises the steps consisting in: i) contacting a binding partner capable of binding specifically to activatable free PSA with a biological sample from a patient suspected of having a benign prostate pathology or an adenocarcinoma of the prostate, i) putting in evidence the capture of the activatable free form of PSA by said binding partner, ⁇ i) calculating the ratio between the quantity of activatable free form of PSA detected in step ii) and the quantity of a form of PSA other than the activatable free form, present in a sample of the same kind taken from the same subject and iv) determine if the patients are affected by an adenocarcinoma of the prostate or by a benign pathology of the prostate by comparing the value of the ratio determined in step i ⁇ ) with a predetermined threshold value, chosen according to the type
- the Applicant has discovered that, unexpectedly, among the binding partners suitable for the purposes of the invention, those recognizing the epitope mimicked by the sequence SEQ ID No. 1 (DTPYPWGWLLDEGYD) were actually able to bind specifically in serum to this activatable free form of PSA without binding or to the denatured or cleaved free PSA, laughed at ProPSA, and that the use of this particular property made it possible to obtain a very sensitive and very specific prostate diagnostic method for pathologies .
- the biological samples in which the method of the invention is implemented are any biological sample likely to contain PSA. By way of example of such samples, mention may be made of seminal fluid, blood, serum, plasma and urine, serum and plasma being particularly preferred.
- Binding partners capable of specifically binding to activatable free PSA suitable for the purposes of the invention include, for example, antibodies, antibody fragments and mirnotopes, as well as any other partner known to those skilled in the art for having this. capacity.
- antibody fragments is generally meant in the present application, any antibody fragment which has retained the specificity of the original antibody, in the present case the ability to bind specifically to the free activatable PSA, and in particular Fab and F (ab ') 2 fragments.
- the word "antibody” also denotes subsequently fragments of antibodies when the sense allows.
- the antibodies useful within the meaning of the invention include in particular purified polyclonal antibodies and monoclonal antibodies.
- polyclonal antibodies and monoclonal antibodies are widely known to those skilled in the art and the principle of this preparation is recalled below.
- the polyclonal antibodies can be obtained by immunization of an animal with at least one target antigen of interest, followed by the recovery of the antibodies sought in purified form, by taking the serum from said animal, and separation of said antibodies from the other constituents of the serum, in particular by affinity chromatography on a column on lacquer, an antigen specifically recognized by the antibodies is fixed, in particular a target antigen of interest.
- the monoclonal antibodies can be obtained by the hybridoma technique, the general principle of which is recalled below.
- an animal generally a mouse
- a double antigen of interest the B lymphocytes of which are then capable of producing antibodies against said antigen.
- These antibody-producing lymphocytes are then fused with myeloma cells
- mimotopes any synthetic or recombinant peptide capable of mimicking a conformation which interacts specifically with said epitope.
- the binding partner capable of binding specifically to the activatable free PSA fulfills at least one of the following conditions: - it is capable of recognizing the epitope mimicked by the sequence SEQ ID No. 1. - it is an antibody or an antibody fragment.
- the sequence SEQ ID No. 1 recognized by the appropriate binding partners for the purposes of the invention mimics a conformational epitope of PSA.
- 1 suitable for the purposes of the invention is the antibody 5D3D11, as described in Michel S., et al., 1999, Clinical Chemistry, 45 (5): 638-650.
- the use of this particular antibody in the process of the invention is unexpected in the sense that this article indicates that this antibody is capable of inhibiting the enzymatic activity of PSA and therefore the binding of ACT, in other words that it is only capable of adhering to an active free form of "open" PSA.
- the Applicant has also shown that it is capable of binding to the activatable free form, that is to say "closed".
- the conjugates consisting of the binding partner capable of binding specifically to the activatable free PSA and of the activatable free form of PSA are new and also constitute an object of the invention.
- said binding partner capable of binding specifically to the activatable free PSA of the conjugate of the invention is a binding partner capable of recognizing the epitope mimed by the sequence SEQ ID No. 1.
- the second step of the diagnostic method of the invention consists in demonstrating the capture of said activatable free form of PSA by said binding partner capable of specifically binding to the activatable free PSA. This step can be carried out directly by detecting the bond between said binding partner and said activatable free form of PSA, or else after elution of said activatable free form of PSA immunocaptured by said binding partner.
- the activatable free form of PSA immunocaptured by said hedgehog partner, then eluted will be called hereinafter.
- Immunopurified activatable free PSA The elution of the activatable free form of PSA immunocaptured by said hedge partner capable of binding specifically to the activatable free PSA can be implemented by any elution method known to those skilled in the art, such as a shock. pH. Preferably, an additive shock is used, for example using a 0.1 M glycine buffer, pH 2.8.
- the detection of the capture of said activatable free form of PSA, whether it is irrmunopurified or not can be carried out by any detection means known in the field of immunoassays, such as direct detection and indirect detection. In the case of indirect detection, i.e.
- a detection partner capable of adhering to the activatable free form of PSA is used.
- This detection partner binds on an epitope different from that used by said binding partner used in step i) when the activatable free PSA is not immunopurified.
- a suitable detection partner for this purpose there may be mentioned antibodies such as anti-total PSA antibodies, which constitutes a mode of reahsation of the invention. Examples of such anti-PSA antibodies capable of recognizing an epitope different from that used by said Haison partner used in step i) are described in the article by Michel S., et al (1999, supra). These detection partners can be previously marked.
- the term “marking” is intended to mean the attachment of a marker capable of directly or indirectly generating a detectable signal.
- a non-limiting Hste of these markers consists of:
- enzymes which produce a detectable signal for example by colorimetry, fluorescence, luminescence, such as horseradish peroxidase, alkaline phosphatase, acetylchoHne esterase, ⁇ -galactosidase, glucose-6-phosphate dehydrogenase,
- chromophores such as luminescent compounds, dyes,
- radioactive molecules such as 32 P, 35 S or 125 I
- Hgand anti-Hgand pair a group consisting of fluorescent molecules, fluorescein, rhodomine, alexa or phycocyanins, and • particles such as gold particles, magnetic latex, Hposomes.
- Indirect labeling systems can also be used, such as, for example, through another Hgand anti-Hgand pair.
- the Hgand / anti-Hgand pairs are well known to those skilled in the art, and the following pairs may be mentioned, for example: biotin / streptavidin, hapten / antibody, antigen / antibody, pepti.de/ antibody, sugar / lectin, polynucleotide / complementary to the polynucleotide. In this case, it is the Hgand which is Hey to the partner of Haison.
- the anti-Hgand can be directly detectable by the markers described in the preceding paragraph or be itself detectable by a Hgand / anti-Hgand. These indirect systems can lead, under certain conditions, to an amplification of the signal. This signal amplification technique is well known to the person skilled in the art. etier, and reference may be made to earlier patent applications FR98 / 10084 or WO95 / 08000 from the Applicant or to article J. Histochem. Cytochem., (1997), 45: 481-491.
- Direct detection of the capture of the Hebre form activatable by said partner of Haison can be implementation for example by plasmon resonance or by cycH voltammetry on an electrode carrying a conductive polymer.
- Direct detection can also be implemented using the specific property of enzymatic activity of active forms of PSA.
- activation of the activatable Hebrew form of PSA should be carried out, if appropriate after its immunopurification.
- the activation of this activatable Hbre form makes it possible to Hbb the Haison site to the enzyme substrate, which can then be reacted with an enzyme substrate.
- the detection is carried out by determining the enzymatic activity of the Hbre form of the immunopurified PSA and activated, which constitutes a particular embodiment of the invention.
- enzymatic substrates which are suitable for the purposes of the invention include all the substrates revealing the chymotrypsic type protease activity widely known to those skilled in the art. Such substrates are available for example from
- Enzyme System Products They are composed of a recognized peptide sequence and cHvée by PSA, this sequence being coupled to a chromophore or fluorophore group.
- the activation of the activatable Hebre form of PSA can be implemented by at least one of the following methods:
- a miHeu of high saline concentration of at least 0.15M, preferably of at least 1M, more preferably of at most 2M, - Season of PSA Hbre activable i munopurified to an antibody capable of increasing the enzymatic activity of PSA, these two methods being able to be implemented separately simultaneously or successively in any order.
- miHeu of high saline concentration of miHeux containing 1.5M NaCl
- an antibody capable of increasing the enzymatic activity of PSA there may be mentioned the antibody 8G8F5 (bioMérieux, France).
- the method of the invention is characterized in that it uses, in addition to the Haison partner capable of specifically targeting Her activable PSA, an antibody capable of increasing the enzymatic activity of PSA , and in particular the antibody 8G8F5.
- This antibody capable of increasing the enzymatic activity of PSA can be used as a capture partner in an ELISA type assay when the Haison partner capable of specifically targeting Her activatable Hebre PSA is used to immunopurify the activatable Hebre PSA.
- the Haison partner capable of specifically targeting the activatable Hebre PSA can also be used as a detection partner, in particular when the Haison partner capable of specifically targeting the activatable Hebre PSA is used as capture partner.
- the conjugates consisting of the Haison partner capable of specifically Herb activating the PSA Hbre, such as a Haison partner capable of recognizing the epitope mimicked by the sequence SEQ ID No. 1, and of the activable Hbre form of the PSA, lacquer is activated, are also new and constitute a particular embodiment of the invention.
- the Haison partners capable of being Her specifically to activatable PSA Hbre, being specifically haunted to activable PSA Hbre can be used as such or in particular in the form fixed on a solid support and / or Hes to a marker.
- the fixation of these Haison partners on a solid support is well known.
- the support can be reacted with any solid, biological or synthetic material, endowed with adsorbent properties or capable of fixing a coupling agent.
- Materials are known and described in the literature.
- the solid materials capable of fixing these partners of Haison by adsorption one will quote for example polystyrene, polypropylene, latex, etc.
- the materials allowing to fix these partners of Haison by oovalence using a coupling agent there may be mentioned in particular dextran, ceUulose, etc.
- the support can be presented, for example, in the form of discs, tubes, tubes, cones or plates, in particular microtiter plates.
- the Haison of Haison partners with a marker will also allow direct detection, as described above. This marker is as previously described.
- the method of the invention can also use a capture partner. In the first case, this capture partner is able to link to an epitope different from that recognized by the partner of Haison capabb to link to the PSA Hbre activable specifically. Examples of capture partner include anti-PSA antibodies, as described above.
- both a capture partner and both a detection partner are used in the method of the invention to assay the Pbre HSA these partners can be activated with different epitopes, themselves being different from the epitope recognized by the Haison partner capable of specifically activating with PSA Hbre activable when PSA
- He activatable was not immunopurified.
- the methods implementing the various partners of the activatable form of PSA for the demonstration of the capture of the activatable Hbre form of PSA by said partner of Haison are widely known to those skilled in the art.
- Step Hi) of the method of the invention consists in calculating the ratio between the quantity of activable Hebre form of PSA detected in stage H) and the quantity of a form of PSA other than said activatable form of the invention , present in a sample of the same nature taken from the same subject
- sample of the same nature taken from the same subject we mean either two fractions of the same sample, or two samples from two different samples but which must be of the same kind, for example serum samples.
- the forms other than the activatable Hbre form of PSA are in particular complexed PSA, total PSA, total PSA Hbre, zymogenic PSA Hbre, denatured PSA Hbre, PSA Hbre cHve and their associations, that is to say all active or inactive forms, Hbre or complexed, of PSA.
- the assay of each of these different forms, in particular using specific antibodies, is known.
- the complexed PSA is assayed for example using antibodies described in patent application WO98 / 22509.
- the total PSA is assayed for example using antibodies described by H. Nagasaki et al. (1999), Clin. Chem. 45: 4486-496.
- the preferred ratios being relative to the quantity of PSA Hbre activatable over the quantity of (denatured PSA Hbre + PSA Hbre cHve) or the quantity of PSA Hbre activatable over the quantity of PSA Hbre inactive.
- the form of PSA other than the activatable Hebre form used to calculate the ratio in step (in) of the process of the invention is the form of denatured Hebre PSA + the form of PSA Hbre chvé or the form of PSA
- the quantity of total PSA the quantity of total PSA Hbre, the quantity of complexed PSA, the quantity of zymogenic PSA Hbre, the quantity of PSA Hbre cHve, the quantity of denatured PSA H is evaluated, the amount of denatured PSA Hbre + PSA Hbre cHve, the amount of denatured PSA Hbre + zymogenic PSA Hbre and the amount of inactive PSA Hbre, or their associations, on a similar sample taken from the same subject, and
- Step iv) of the method of the invention consists in determining whether the patients are affected by an adenocarcinoma of the prostate or by a benign pathology of the prostate by comparing the value of the ratio determined in step Hi) with a value- predetermined threshold, chosen according to the type of report used and representative of the detection limit for each pathology.
- a value- predetermined threshold chosen according to the type of report used and representative of the detection limit for each pathology.
- a threshold value is called either a discrete value, or an interval of values corresponding to a zone of determination. Obviously, when the measured value is included in the indeterminacy interval, or is very close to the threshold value in the case of a discrete value, one cannot definitively conclude and additional investigations should be carried out. Of course, when a threshold value has been determined for a given type of report, it can be deduced therefrom threshold values corresponding to other types of reports.
- the invention also relates to a diagnostic kit making it possible to diagnose an adenocarcinoma of the prostate or a benign pathology of the prostate, said kit comprising:
- Haison partner capable of specifically targeting Her activable Hbre PSA, preferably a Haison partner capable of recognizing the epitope mimicked by the sequence SEQ ID No. 1, more preferably an antibody or an antibody fragment, and,
- Means for assaying forms of PSA other than the activatable Hbre form preferably antibodies or antibody fragments.
- Such means which can be used in said kit are as described above for the determination of the form of PSA which it is desired to quantify.
- the method of the invention can also be implemented by using a partner of Haison capable of getting Her to the PSA Hbre non-specifically activatable.
- partners can be partners capable of integrating with total PSA, including in particular activatable Hebre PSA.
- This Haison partner capable of being linked to non-specifically activable Hbre PSA can be used in the process of the invention as described above with the Haison partner capable of being specifically activated to activable Hbre PSA, namely as capture partner. or to immunopurify PSA Hbre.
- the detection of the activatable Hebre form of PSA must be implemented using the particular property of enzymatic activity of the active forms of PSA. In this case, the activatable Hbre form of PSA should be activated.
- this activatable free form makes it possible to Hbb the Haison site to the enzyme substrate, which can then be reacted with an enzyme substrate as described above.
- the detection is implemented by determining the enzymatic activity of the Hbre form of the activated PSA.
- the invention relates to a diagnostic method a benign prostate pathology or an adenocarcinoma of the prostate according to claim 1, characterized in that it comprises the steps consisting in: i) bringing into contact a partner of Haison capable of being Her with PSA Hbre activatable in a non-specific manner, with a biological sample from a patient suspected of having a benign prostate pathology or an adenocarcinoma of the prostate, ⁇ ) highlight the capture of the activatable Hebre form of PSA by said partner of Haison by determination of the enzymatic activity of the Hbre form of activated PSA, after activation of the activable Hbre form of PSA ⁇ i) calculate the ratio between the quantity of activable Hbre form of PSA detected in step H) and the quantity of a form of PSA other than the activatable Hbre form, present in a similar sample taken from the same subject and iv) determining whether the patients are affected by an adenocarcinoma of the prostate or by
- a miHeu of high saline concentration of at least 0.15M, preferably of at least 1M, more preferably of at most 2M, as described above,
- the method of the invention is characterized in that it uses, in addition to the Haison partner capable of taking up the PSA Hbre activatable so non-specific, an antibody capable of increasing the enzymatic activity of PSA, and in particular the antibody 8G8F5.
- This antibody capable of increasing the enzymatic activity of PSA can be used as such, in an assay, as a capture partner for activable PSA Hebre previously immunopurified in a specific or non-specific manner from biological samples.
- HSA PSA thus activated after its capture by the antibody will be detected by its enzymatic activity which will be measured via kinetics of hydrolysis of a fluorescent substrate.
- the slope of the kinetics will be expressed in fluorescence units.
- the correspondence in quantities of PSA will be obtained thanks to a standard curve curve with quantities of active PSA, between With the exception of the above, steps i) to iv) of this particular embodiment are as described above. the present invention will be better understood with the aid of the following examples given solely by way of illustration and without limitation, as well as with the aid of the appended FIGS. 1 to 6, on which: - FIG.
- FIG. 2 represents a standardization graph giving the fluorescence as a function of the PSA concentration obtained by using seminal PSA previously in-tmunopurified with the antibody 5D3D11 and assayed in total PSA,
- FIG. 3 is a graphical representation giving the values of the PSA activable / (PSA Hbre cHve + PSA Denatured PSA) ratios obtained with the method of the invention for serum from patients with prostate cancer and treated by radiotherapy (RT ), by hormone therapy (HT) or by prostatectomy (PR), of patients with cancer but whose treatment is not known (others), of patients with benign hyperplasia (BPH) and of normal patients (PN) (part A of the graph), as well as the values of the PSA Hbre PSA total ratios obtained according to a process of the prior art (part B of the graph) with these same sera,
- RT radiotherapy
- HT hormone therapy
- PR prostatectomy
- BPH benign hyperplasia
- PN normal patients
- FIG. 4 is a graphical representation giving the values of the PSA ratios activable / (PSA Hbre cHve + PSA Hbre denatured) obtained with the method of the invention in sera having a PSA Hbre / PSA total ratio of between 0.15 and 0.25, the sera being from patients suffering from cancer prostate and treated with radiotherapy (RT), hormone therapy (HT) or prostatectomy (PR), patients with cancer but whose treatment is unknown (others), patients with benign hyperplasia (BPH) and of normal patients (PN), - Figure 5 is a graphical representation giving the values of the PSA activable / (PSA Hbre cHve + PSA Denatured PSA) ratios for the sera of patients with prostate cancer and patients with hyperplasia benign (BPH), with a total PSA level of less than 2.5 ng / ml, and
- FIG. 6 is a graphical representation giving the values of the activatable PSA / (PSA Hbre cHve + PSA Hbre denatured) ratios for the sera of patients with prostate cancer and patients with benign hyperplasia (BPH), obtained with the antibody 5D5A5 or the antibody 11E5C6 as anticoips for detection of activatable PSA.
- Preparation of LNCaP supernatants PSA was synthesized by the LNCaP eye strain according to the technique described in the articles "LNCaP Produces both putative zymogen and inactive, free form of prostate specifies antigen "E. Corey et al., 1998, Prostate 35: 135-143," Androgen-Sensitive human prostate cancer ceH, LNCaP, Produce both N-terminaUy mature and tuncated prostate specifies antigen isoform "To Herrala et al., 1997, Eur. J. Biochem.
- the whole was then covered with oil paraffin, and incubated overnight.
- the separation was carried out under a voltage increasing linearly from 100 to 3500 N in 8 h, and a step of focusing at 6000 N was carried out for 80 to 100 kVh.
- the proteins having focahsed at their isoelectric point were then separated in a second dimension according to their size thanks to SDS -PAGE electrophoresis, on a large homogeneous 12% acrylamide gel at 40 mA per gel, for 5-6 h, according to the conventional protein electrophoresis technique.
- the gels obtained after separation according to the second dimension were transferred onto a PVDF membrane (polyvinyhdene trifluoride; MiUipore) in CAPS / methanol buffer (add 3- [cyclohexilamino] -l-propanesulfonic), for 1 night under a current of 1 A, maintaining the temperature at 15 ° C.
- the membranes were saturated overnight at 4 ° C. in TBS (Tris Buffer Saline, Tris 15 mM pH 8, ⁇ aCl 140 mM) containing 0.05% of Tween 20 and 5% of dehydrated skimmed milk.
- TBS Tris Buffer Saline, Tris 15 mM pH 8, ⁇ aCl 140 mM
- the anti-PSA 13C9E9 antibody previously identified to detect all forms of PSA (Charrier JP, et al., 2001, Electrophoresis, 22, 1861- 1866), was diluted in the saturation solution to 10 ⁇ g / l, and was added to the membranes. After an incubation of 1 h at 37 ° C, the membranes were washed three times (5 min) with a saturation solution, and brought into contact with the anti-mouse antibody conjugate coupled to peroxidase (Jackson ImmunoResearch, West Grove , United States of America), diluted to l / 5000 th in the saturation solution. They were then incubated for 1 h at room temperature, washed three times in saturation solution.
- the immunoreactivity was detected by using a chemHuminescent substrate (Pierce), by incubating the membranes in Fluor S, and by making an acquisition of the image (between 1 min. And 1 h depending on the sample).
- the images obtained were then processed using the Multi-Analyst software (Biorad).
- the photographs of these gels are reproduced in FIG. 1 where the photograph A corresponds to the use of the antibody 5D3D11, the photograph B corresponds to the use of the antibody 6C8D8 and the photograph C corresponds to the antibody 11E5C6 (Michel S. et al., 1999, supra) which is a total anti-PSA antibody used for comparison.
- PSA immunopurified with the anti-total PSA antibody 11E5C6 shows that, in comparison with PSA immunopurified with the anti-total PSA antibody 11E5C6, PSA immunopurified with the antibody 5D3D11 has very little chvee or truncated forms. On the other hand, these forms are present in a much greater proportion in PSA in-u unopurified with the antibody 6C8D8.
- the PSA bands were stained with a 0.25% solution of Rouge Ponceau S in 3% TCA (trichloroacetic acid), and the band corresponding to mature PSA (approximately 30 kDa) was cut out and subjected to degradation of 'Edman on a Procise 292A protein sequencer (AppHed Biosystems).
- the results obtained showed that the PSA immunopurified by the antibody 5D3D11 contained only the mature form (GG 7), while the PSA immunopurified by the antibody 6C8D8 contained the mature form, as well as the proPSA (-7) and proPSA (-5).
- the total anti-PSA antibody can be either the 11E5C6 antibody which does not modify the enzymatic activity of PSA (Michel S. et al., 1999, supra), or the 8G8F5 antibody (bioMérieux, France).
- the wells were washed with 0.05% TBS-Tween, and the PSA immunopurified by antibodies 5D3D11 or 6C8D8, diluted in TBS-BSA to 2.5 ⁇ g ml was introduced and incubated overnight at 4 ° C. The wells were then washed again in 0.05% TBS-Tween and incubated for 15 min.
- the enzymatic activity is expressed in fluorescence units x 1000 / min.
- This table shows that the PSA immunopurified by the antibody 5D3D11 has a detectable enzymatic activity. This activity is increased in the presence of 1.5 M NaCl.
- the capture of PSA by the antibody 8G8F5 also increases the enzymatic activity of PSA.
- This example demonstrates that, among the active Hbre forms of PSA in the LNCaP cells, there is the activatable Hbre form which is detectable according to the method of the invention.
- Example 2 Detection of the activatable free form of PSA from serum from patients with prostate adenocarcinoma
- the serum pool used is composed of 30 sera from patients with prostate cancer.
- PSA concentration of this pool total PSA: 71 ng / ml; PSA Hbre: 12 ng / ml, determined using FappareU Vidas.
- the resin described in paragraph 1.2 is used as a solid support having fixed the antibodies 5D3D11 and 6C8D8. 50 ⁇ l of these resins are brought into contact with 1 ml of the serum pool described above overnight at 4 ° C. with stirring.
- the tubes are then centrifuged, the fraction containing the unbound PSA was kept, the resin was washed 3 times with 0.5% PBS-Tween (the washing fractions are combined and stored), then the PSA fixed by the antibody 5D3D11 or 6C8D8 was eluted for 5 min with 200 ⁇ l of 0.1 M Glycine PH 2.2 containing 1 mg / ml of BSA and neutralized at pH 7.2 with 2 M Tris pH 8. 2.1.
- Measurement of the enzyme activity of immunopurified PSA from serum The wells of a black Nunc Maxisorp ELISA plate (compatible with fluorescence detection) were “coated” for 2 hours at 37 ° C.
- the total anti-PSA antibody can be: o either the 11E5C6 antibody, which does not modify the enzymatic activity of PSA, o or the 8G8F5 antibody which increases the enzymatic activity of the captured PSA.
- the wells were washed with 0.05% TBS-Tween, and 100 ⁇ l of PSA immunopurified from serum with the antibodies 5D3D11 or 6C8D8 were introduced and incubated overnight at 4 ° C. The wells were then washed again in 0.05% TBS-Tween and incubated for 15 min with TBS-BSA 2 mg / ml, the NaCl concentration of which was raised to 1.5 M.
- the enzymatic activity is expressed in fluorescence units x 1000 / minute. * The activity measured directly from the serum (without immunopurification) is underestimated, because the activated PSA immediately complexes with serum FACT.
- This table shows that we are able to measure an enzymatic activity on PSA immunopurified from serum: the serum therefore contains activatable PSA Hbre. There is always a significant difference in activity between the PSA immunopurified by the antibody 5D3D11 and that immunopurified by the antibody 6C8D8, showing that the antibody 5D3D11 specifically recognizes the activatable PSA Hbre.
- Example 3 Use of the antibody 5D3D11 in a diagnostic test for the discrimination between a BPH and adenocarcinoma of the prostate
- the Vidas apparatus was used, adapted to include the appropriate assay reagents, but used according to the instructions of the supplier (bioMérieux, France).
- 3.1 Determination of activatable PSA in patient sera The antibody 5D3D11 is used as capture antibody in a sandwich type test.
- the PSA captured is detected by the total anti-PSA antibody 5D5A5 coupled with alkaline phosphatase.
- the protocol is as described above.
- the standardization of the test was carried out according to the supplier's recommendations using seminal PSA immunopurified with the antibody 5D3D11 and assayed in total PSA.
- the detection limit of the test is 0.05 ng / ml of active PSA / ml.
- the standardization curve in the concentration range from 0 to 1.5 ng / ml is shown in Figure 2. This curve, which is close to a straight line, shows that the assay with a Haison partner recognizing the epitope mimicked by the sequence SEQ ID No. 1 makes it possible to detect PSA Hbre activatable with good sensitivity.
- prostate cancers well identified with total PSA levels, tumor grades, Gleason scores and any information on treatments (radiotherapy, hormone therapy, prostatectomy or unknown) carried out subsequently - 65 benign hyperplasias,
- the activable PSA Hbre / / ratio (PS A denatured Hbre + PSA Hbre cHve) obtained using the previous assays was calculated and these values were reproduced on the graph of FIG. 3, part A As well as the shows part A of FIG. 3, using a threshold of 0.66 for sera having a total PSA level of between 2.5 and 10 ng / ml, the PSA activatable / / (PSA Hebre cHve + PSA Hebre denatured) ratio ) characterizes 22/33 cancers (67%), 19/19 normal prostates (100%) and 27/28 BPH (96%).
- the PSA Hbre to total PSA ratio was calculated using two Vidas kits (Kit PSA total and Kit PSA Hbre, bioMérieux, France) according to the supplier's recommendations. The results are reproduced on part B of the graph in FIG. 3. This part B shows that U exists an uncertainty zone for values from 0.15 to 0.25.
- 3.4 Sensitivity of the process of the invention 3.4.1
- the values of the activable PSA Hbre / / (denatured PSA Hbre + PSA Hbre cHve) ratios obtained according to the method of the invention for the 28 sera the area of uncertainty obtained with the method of the prior art has been reproduced in FIG. 4.
- Example 4 Detection of the activatable free form of PSA from a binding partner capable of binding in a non-specific manner to the activatable free PSA in a biological sample 1.
- Samples used Nine individual sera were used having total PSA concentrations varying from 157 at 3.8 ng / ml and coming from the CHU of Liège, that is to say from the hospital of the Armies, Desgenettes, located in Lyon. 2.
- the TPSA test has a sensitivity of 0.07 ng / ml PSA and can detect up to 100 ng / ml PSA.
- the FPSA test has a sensitivity of 0.05 ng / ml and can detect up to 10 ng / ml of PSA. 4. Measurement of the enzymatic activity of PSA 4.1. Fixation of capture antibodies The wells of an ELISA plate were coated with 100 ⁇ l of streptavin (Hluée at 10 ⁇ g / ml in carbonate buffer pH 9.6, and incubated for 2 h at 37 ° C.
- sera 1 and 9 come from patients confirmed as having prostate cancer, which is also confirmed by the method of the invention.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/590,272 US20070254317A1 (en) | 2004-03-03 | 2005-03-01 | Method for Detecting the Activatable Free Form of Psa and the Use Thereof for Diagnosing Benign Pathologies of the Prostate and Adenocarcinoma of the Prostate |
EP05739674A EP1723430A2 (fr) | 2004-03-03 | 2005-03-01 | Procede de detection de la forme libre activable du psa et son utilisation pour le diagnostic des pathologies benignes de la prostate et de l adenocarcinome de la prostate |
JP2007501328A JP2008509379A (ja) | 2004-03-03 | 2005-03-01 | 活性化可能な遊離型psaの検出方法、並びに、前立腺の良性病状及び前立腺ガンの診断におけるその使用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0450426 | 2004-03-03 | ||
FR0450426 | 2004-03-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005085292A2 true WO2005085292A2 (fr) | 2005-09-15 |
WO2005085292A3 WO2005085292A3 (fr) | 2006-02-09 |
Family
ID=34917350
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2005/050132 WO2005085292A2 (fr) | 2004-03-03 | 2005-03-01 | Procede de detection de la forme libre activable du psa et son utilisation pour le diagnostic des pathologies benignes de la prostate et de l'adenocarcinome de la prostate |
Country Status (5)
Country | Link |
---|---|
US (1) | US20070254317A1 (fr) |
EP (1) | EP1723430A2 (fr) |
JP (1) | JP2008509379A (fr) |
CN (1) | CN1926433A (fr) |
WO (1) | WO2005085292A2 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010515064A (ja) * | 2006-12-29 | 2010-05-06 | アボット・ラボラトリーズ | 免疫抑制剤の改善された測定法 |
JP2010528261A (ja) * | 2007-05-08 | 2010-08-19 | ピコベラ・リミテッド・ライアビリティ・カンパニー | 前立腺癌および肺癌の診断および治療方法 |
CN101158687B (zh) * | 2007-06-11 | 2012-09-05 | 吉林大学 | 多肽psa2在制备前列腺癌诊断试剂盒中的应用 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009026177A1 (fr) | 2007-08-17 | 2009-02-26 | Purdue Research Foundation | Conjugués ligand-lieur de liaison au psma et procédés pour utiliser ceux-ci |
CN101765784B (zh) * | 2008-02-15 | 2013-06-26 | 综合测试电子系统有限公司 | 用于将多个分离成单件的半导体器件保持并定向在接线端支架的容纳凹部中的装置和方法 |
US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
JP2013528379A (ja) * | 2010-05-21 | 2013-07-11 | オームクス コーポレーション | Psa酵素活性アッセイによる癌の検出 |
US20130277305A1 (en) * | 2012-04-19 | 2013-10-24 | Lockheed Martin Corporation | Selectively perforated graphene membranes for compound harvest, capture and retention |
EA201590783A1 (ru) | 2012-11-15 | 2015-11-30 | Эндосайт, Инк. | Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma |
CN104007256A (zh) * | 2013-02-21 | 2014-08-27 | 林斯 | 总psa和游离psa二合一化学发光免疫诊断试剂盒的制备方法 |
CN105636924B (zh) | 2013-10-18 | 2018-08-07 | 德国癌症研究中心 | 前列腺特异性膜抗原(psma)的标记的抑制剂,它们作为显影剂和用于治疗前列腺癌的药剂的用途 |
US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
CN108603883A (zh) * | 2016-01-27 | 2018-09-28 | 富士胶片和光纯药株式会社 | 前列腺癌的判定方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000002052A1 (fr) * | 1998-07-03 | 2000-01-13 | Bio Merieux | Methode de diagnostic d'un adenocarcinome ou d'une pathologie benigne de la prostate |
WO2001077180A1 (fr) * | 2000-04-10 | 2001-10-18 | Bio Merieux | Anticorps reconnaissant specifiquement le psa inactif, et leurs applications |
WO2001096876A1 (fr) * | 2000-06-13 | 2001-12-20 | Biomerieux S.A. | Test immunologique et kit de diagnostic d'un adenocarcinome de la prostate |
-
2005
- 2005-03-01 WO PCT/FR2005/050132 patent/WO2005085292A2/fr not_active Application Discontinuation
- 2005-03-01 CN CNA2005800066633A patent/CN1926433A/zh active Pending
- 2005-03-01 EP EP05739674A patent/EP1723430A2/fr not_active Withdrawn
- 2005-03-01 JP JP2007501328A patent/JP2008509379A/ja active Pending
- 2005-03-01 US US10/590,272 patent/US20070254317A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000002052A1 (fr) * | 1998-07-03 | 2000-01-13 | Bio Merieux | Methode de diagnostic d'un adenocarcinome ou d'une pathologie benigne de la prostate |
WO2001077180A1 (fr) * | 2000-04-10 | 2001-10-18 | Bio Merieux | Anticorps reconnaissant specifiquement le psa inactif, et leurs applications |
WO2001096876A1 (fr) * | 2000-06-13 | 2001-12-20 | Biomerieux S.A. | Test immunologique et kit de diagnostic d'un adenocarcinome de la prostate |
Non-Patent Citations (4)
Title |
---|
COREY E. ET AL.: "LNCaP produces both putative zymogen and inactive, free form of prostate-specific antigen." THE PROSTATE, vol. 35, 1998, pages 135-143, XP000981985 * |
LILJA H.: "Biology of prostate-specific antigen." UROLOGY, vol. 62, no. 5, novembre 2003 (2003-11), pages 27-33, XP002286825 * |
MICHEL S. ET AL.: "Anti-free prostate-specific antigen monoclonal antibody epitopes defined by mimotopes and molecular modeling." CLIN. CHEM., vol. 45, no. 5, mai 1999 (1999-05), pages 638-650, XP002175112 cité dans la demande * |
MICHEL S. ET AL.: "Selective recognition of enzymatically active prostate-specific antigen (PSA) by anti-PSA monoclonal antibodies." J. MOL. RECOGNIT., vol. 18, no. 3, mai 2005 (2005-05), pages 225-235, XP009055674 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010515064A (ja) * | 2006-12-29 | 2010-05-06 | アボット・ラボラトリーズ | 免疫抑制剤の改善された測定法 |
JP2010528261A (ja) * | 2007-05-08 | 2010-08-19 | ピコベラ・リミテッド・ライアビリティ・カンパニー | 前立腺癌および肺癌の診断および治療方法 |
CN101158687B (zh) * | 2007-06-11 | 2012-09-05 | 吉林大学 | 多肽psa2在制备前列腺癌诊断试剂盒中的应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2005085292A3 (fr) | 2006-02-09 |
JP2008509379A (ja) | 2008-03-27 |
CN1926433A (zh) | 2007-03-07 |
US20070254317A1 (en) | 2007-11-01 |
EP1723430A2 (fr) | 2006-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1723430A2 (fr) | Procede de detection de la forme libre activable du psa et son utilisation pour le diagnostic des pathologies benignes de la prostate et de l adenocarcinome de la prostate | |
JPH10177027A (ja) | cPSAの測定方法 | |
US20030059864A1 (en) | Method of analyzing non-complexed forms of prostate specific antigen in a sample to improve prostate cancer detection | |
CA2336174C (fr) | Methode de diagnostic d'un adenocarcinome ou d'une pathologie benigne de la prostate | |
Park et al. | Interference-free duplex detection of total and active enzyme concentrations at a single working electrode | |
JP2024026847A (ja) | 完全長の高分子量キニノーゲン(hmwk)と切断されたhmwkとを区別するためのペプチド定量アッセイ | |
EP1295125B1 (fr) | Test immunologique et kit de diagnostic d'un adenocarcinome de la prostate | |
EP1088232B1 (fr) | Procede et trousse de diagnostic precoce du cancer | |
EP3207371B1 (fr) | Composition pour dosage immuno-enzymatique par immunofluorescence et ses utilisations | |
EP2649452B1 (fr) | Procede et coffret pour le diagnostic in vitro du cancer de la prostate | |
EP1272525B1 (fr) | Anticorps reconnaissant specifiquement le psa libre inactif, et leurs applications | |
JP7128827B2 (ja) | 固定分析物 | |
JP4043053B2 (ja) | 生物学上の流体中のプロカルボキシペプチダーゼaおよびカルボキシペプチダーゼaレベルの検出方法 | |
CN113929748A (zh) | 检测bace1酶活性的试剂盒及用途 | |
JP5640271B2 (ja) | 新規ペプチド及びその使用 | |
KR102677901B1 (ko) | 보체 C4d 분석 | |
JP2001509270A (ja) | 生物学的液体中のPSA−α2−マクログロブリン複合体の検出 | |
US20130116133A1 (en) | Methods and materials for the diagnosis of prostate cancers | |
Ejaz et al. | Indirect Back-Titration ELISA: A New Format for Estimation of Human Tissue Kallikreins | |
FR2857453A1 (fr) | Procede de detection serologique de la maladie coeliaque et necessaire de diagnostic associe | |
KR20210015259A (ko) | 방광암 진단 또는 예후 분석용 바이오마커 조성물, 키트 및 이를 이용한 진단 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005739674 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10590272 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007501328 Country of ref document: JP Ref document number: 200580006663.3 Country of ref document: CN Ref document number: 5043/DELNP/2006 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005739674 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2005739674 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10590272 Country of ref document: US |